Condition: Multiple Myeloma and Other Plasma Cell Neoplasms · Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
This study is a 2-part study with a dose-escalation part and a dose-expansion part. The aim of the dose-escalation part is to determine the maximum tolerated dose (MTD) and/or establish the recommended Phase 2 dose (RP2D) in the Chinese population, in order to select the treatment dose for the dose-expansion part. The dose-escalation part will be followed by the dose-expansion part once the MTD(s) and/or RP2D of HDP-101 monotherapy in the Chinese population have been determined. The dose-expansion part of the study is intended to collect preliminary evidence of antitumor activity and to confirm the safety of the HDP-101 as monotherapy in Chinese patients with r/r MM.
This description comes directly from the study's public registry record.
Jianfei Zhao · +8618428347838 · zhaojianfei@eastchinapharm.com
Always discuss trial participation with your own doctor first.
| Beijing Chao-Yang Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07529782